Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:16:35 EDT Fri 26 Apr 2024
Enter Symbol
or Name
USA
CA



Q:COCP - COCRYSTAL PHARMA INC - http://cocrystalpharma.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
COCP - Q0.61.50·1.710.11.54+0.021.329.540521.5516  1.581  1.50013.285  1.32519:19:56Mar 2815 min RT 2¢

Recent Trades - Last 10 of 52
Time ETExPriceChangeVolume
19:19:56Q1.485-0.0251
15:59:57Q1.57130.06133
15:59:57Q1.57130.061354
15:59:57Q1.57130.061343
15:58:44Q1.57750.06754
15:57:54Q1.5550.04533
15:40:35Q1.540.02114
14:38:01Q1.540.033
13:56:19Q1.5450.025100
13:52:52Q1.52920.01921

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-03-28 08:00U:COCPNews ReleaseCocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
2024-03-19 08:00U:COCPNews ReleaseCocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A
2024-03-05 08:34U:COCPNews ReleaseCocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap
2024-01-04 08:00U:COCPNews ReleaseCocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates
2023-12-06 08:00U:COCPNews ReleaseCocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A
2023-11-29 08:00U:COCPNews ReleaseCocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast
2023-11-27 08:00U:COCPNews ReleaseCocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023
2023-11-13 08:00U:COCPNews ReleaseCocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
2023-11-09 08:00U:COCPNews ReleaseCocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast
2023-10-31 08:00U:COCPNews ReleaseCocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344
2023-09-28 08:00U:COCPNews ReleaseCocrystal Pharma Doses First Subjects in Clinical Study of CDI-988 For Pandemic Norovirus and Coronavirus
2023-09-05 08:00U:COCPNews ReleaseCocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference
2023-08-14 08:00U:COCPNews ReleaseCocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
2023-08-08 08:00U:COCPNews ReleaseCocrystal Pharma Selects Novel Oral Protease Inhibitor CDI-988 as Norovirus Lead
2023-05-31 08:00U:COCPNews ReleaseCocrystal Pharma Receives HREC Approval to Initiate Phase 1 Study to Evaluate Oral Broad-Spectrum Coronavirus 3CL Protease Inhibitor CDI-988
2023-05-15 08:00U:COCPNews ReleaseCocrystal Pharma Reports First Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
2023-05-04 16:05U:COCPNews ReleaseCocrystal Pharma Presents New Data from its CC-42344 Phase 1 Influenza A Study at the 7th Annual ISIRV Antiviral Group Conference